Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2022-04-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
第四届董事会第三十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Tianjin Ruipu Biotechnology Co., Ltd. It includes approval of the 2022 first quarter report, appointment of a financial officer, approval of a restricted stock incentive plan draft and related management measures, authorization for the board to handle matters related to the stock incentive plan, approval of a related party transaction, and the proposal to convene an extraordinary general meeting to approve these matters. The document contains voting results for each resolution and detailed descriptions of the agenda items. It is not the full quarterly report itself but a board meeting resolution announcement that references the quarterly report and other documents disclosed elsewhere. The document length is 4603 characters, which is relatively short and mainly serves as a formal announcement of board decisions and upcoming shareholder meeting proposals. Therefore, it fits best into the category of Board/Management Information (MANG), as it announces board meeting resolutions including management appointments and corporate governance decisions.
2022-04-28 Chinese
天津瑞普生物技术股份有限公司2022年限制性股票激励计划实施考核管理办法
Remuneration Information Classification · 95% confidence The document is titled as the "2022 Restricted Stock Incentive Plan Implementation Assessment Management Measures" of Tianjin Ruipu Biotechnology Co., Ltd. It details the assessment criteria, principles, scope, and procedures for the company's restricted stock incentive plan for 2022-2024. The content focuses on the management and evaluation of stock incentives for directors, senior management, and key personnel, including performance targets and assessment mechanisms. There is no indication that this is a full annual report, earnings release, or financial statement. Instead, it is a governance-related document concerning executive compensation and incentive plans. It is not a proxy solicitation or remuneration report but rather a management/governance policy document. Therefore, the best fitting category is Remuneration Information (DEF 14A), which covers reports detailing compensation and incentive plans for executives and directors. The document length is 2371 characters, which is consistent with a detailed policy document rather than a brief announcement or a full report.
2022-04-28 Chinese
关于控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder. It details the number of shares pledged, the proportion of shares involved, and the impact on company operations and governance. There is no financial data, no report or presentation attached, and no mention of voting results or management changes. The document is a regulatory announcement about share pledging, which fits the category of Capital/Financing Update (CAP). The document length is short and focused solely on the pledge event, not a full report or financial statement.
2022-04-28 Chinese
独立董事对第四届董事会第三十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board matters including a 2022 restricted stock incentive plan, related performance indicators, an investment transaction, and the appointment of a financial officer. It references compliance with laws and regulations and provides detailed opinions on these corporate governance and management issues. The document is not a financial report, earnings release, or regulatory filing per se, but rather a formal board/management related opinion document. It does not announce voting results, nor is it a proxy or remuneration report. The content aligns best with Board/Management Information (MANG) as it concerns board meeting matters and management appointments.
2022-04-28 Chinese
天津瑞普生物技术股份有限公司2022年限制性股票激励计划（草案）
Board/Management Information Classification · 95% confidence The document is a detailed draft of a 2022 restricted stock incentive plan by Tianjin Ruipu Biotechnology Co., Ltd. It includes comprehensive information about the stock incentive plan such as purpose, management, scope, stock source, quantity, allocation, validity period, grant date, lock-up period, grant price, conditions for granting and lifting restrictions, performance targets, accounting treatment, and implementation procedures. It is a formal plan document related to equity incentives for management and key personnel, not a financial report, earnings release, or announcement of voting results. It is not a proxy solicitation or remuneration report but a detailed management-related plan document. Therefore, the document fits best under Board/Management Information (MANG) as it relates to management incentive plans and governance of senior management compensation and stock incentives.
2022-04-28 Chinese
第四届监事会第三十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Tianjin Ruipu Biotechnology Co., Ltd. It details the approval of the company's 2022 first quarter report, stock incentive plans, and related matters. The text references the approval of the full 2022 first quarter report but does not contain the report itself or detailed financial statements. It also mentions that the full report is available on the China Securities Regulatory Commission designated disclosure website. The document is relatively short (2787 characters) and serves as an official announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2022-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.